tirzepatide through lilly FDA says the weight-loss drug shortage is over A Study of Tirzepatide (LY3298176)

Phase 2 trial data (Jastreboff et al., NEJM, 2023) showed mean body weight reductions of approximately 24% at 48 weeks with the highest dose, with no clear plateau observed

Plasma FABP1 levels are significantly elevated in AD patients and are positively correlated with cerebrospinal fluid (CSF) total tau and phosphorylated tau

Are GLP-1 medications safe in pregnancy or breastfeeding

Safety considerations require clinical vigilance

When it comes to weight management and GLP-1 coverage: Some MA plans may offer fitness benefits like gym memberships (SilverSneakers, Renew Active) that support weight management goals Formulary differences matter: Each MA plan with drug coverage has its own formulary, so GLP-1 coverage for approved conditions (diabetes, cardiovascular risk) can vary significantly from plan to plan GLP-1 Bridge access: MA plans that include prescription drug coverage (MA-PD plans) are included in the GLP-1 Bridge program, so members of those plans can participate starting July 2026 Supplemental benefits: Some MA plans offer nutritional counseling, meal delivery, or wellness programs that can complement weight management efforts If weight management is a priority for you, it's worth comparing how different plans handle these benefits